Rupatadine Fumarate

SKU: orb1300945

Description

Rupatadine Fumarate (UR-12592 Fumarate) is a dual antagonist of platelet-activating factor (PAF) and the histamine H1 receptor, exhibiting high potency with respective Ki values of 0.55 µM and 0.1 µM. This small molecule is utilized in research to study allergic inflammation and anaphylaxis, with applications in both in vitro binding assays and in vivo models of allergic response.

Research Area

Cell Biology, Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 182349-12-8
• MW: 532.03
• Purity: 99.86%
• Formula: C₂₆H₂₆ClN₃·C₄H₄O₄
• SMILES: OC(=O)\C=C\C(O)=O.Cc1cncc(CN2CC\C(CC2)=C2/c3ccc(Cl)cc3CCc3cccnc23)c1
• Target: Autophagy,Histamine Receptor,PAFR
• Solubility: Ethanol:11 mg/mL (20.68 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.76 mM);DMSO:12 mg/mL (22.56 mM)

Bioactivity

• Target IC50:
  PAF receptor:550 nM(Ki)|H1 receptor:102 nM(Ki)
• In Vivo:
  Rupatadine blocks histamine- and PAF-induced effects in vivo, such as hypotension in rats (ID50 = 1.4 and 0.44 mg/kg i.v., respectively) and bronchoconstriction in guinea pigs (ID50 = 113 and 9.6 μg/kg i.v.). Moreover, it potently inhibits PAF-induced mortality in mice (ID50 = 0.31 and 3.0 mg/kg i.v. and p.o., respectively) and endotoxin-induced mortality in mice and rats (ID50 = 1.6 and 0.66 mg/kg i.v.). Rupatadine's duration of action is long, as assessed by the histamine- and PAF-induced increase in vascular permeability test in dogs (42 and 34% inhibition at 26 h after 1 mg/kg p.o.). Rupatadine at a dose of 100 mg/kg p.o. neither modifies spontaneous motor activity nor prolongs barbiturate-sleeping time in mice, which indicates a lack of sedative effects.
• In Vitro:
  Rupatadine inhibits both platelet-activating factor (PAF) and histamine (H1) effects through its interaction with specific receptors. Rupatadine competitively inhibits histamine-induced guinea pig ileum contraction (pA2 = 9.29 ± 0.06) without affecting contraction induced by ACh, serotonin or leukotriene D4(LTD4). It also competitively inhibits PAF-induced platelet aggregation in washed rabbit platelets (WRP) (pA2= 6.68 ± 0.08) and in human platelet-rich plasma (HPRP) (IC50 = 0.68 μM), while not affecting ADP- or arachidonic acid-induced platelet aggregation. In another study, it is reported rupatadine and loratadine shows similar inhibitory effect on histamine and TNF-α release, whereas SR-27417A only exhibits inhibitory effect against TNF-α.
• Cell Research:
  Platelet aggregation is induced by C18-PAF and measured by using a dual-channel aggregometer Chrono-log 560. Platelet aggregation in the absence and in the presence (5-min incubation) of the test compounds is recorded. Activity of the inhibitors is expressed as the IC50 values. To assess selectivity, rupatadine is tested against other aggregating agents, including arachidonic acid (1 mM) and ADP (5 μM), in WRP. Dose-response curves for PAF-induced aggregation in WRP are obtained in the absence of rupatadine and in its presence at various concentrations (3 × 10-7–3 × 10-5 M).(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Rupafin, Rupatadine, Rupatadine Fumarate, rhinitis, Rinialer, urticaria, UR 12592, UR12592, UR-12592, Autophagy, Alergoliber, allergic, PAFR, PAF, Inhibitor, inhibit, Histamine Receptor, HistamineReceptor, H1 receptor

Compound Identifiers

PubChem CID

6449107